Methods for improving bioavailability of a renin inhibitor

Details for Australian Patent Application No. 2005268844 (hide)

Owner Novartis AG

Inventors Camenisch, Gian P.; Gross, Gerhard; Wasmuth, Daniel; Ottinger, Isabel

Agent Davies Collison Cave

Pub. Number AU-B-2005268844

PCT Pub. Number WO2006/013094

Priority 60/598,700 03.08.04 US

Filing date 2 August 2005

Wipo publication date 9 February 2006

Acceptance publication date 5 March 2009

International Classifications

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61K 38/13 (2006.01) Medicinal preparations containing peptides

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 9/12 (2006.01) Drugs for disorders of the cardiovascular system

Event Publications

15 February 2007 PCT application entered the National Phase

  PCT publication WO2006/013094 Priority application(s): WO2006/013094

5 March 2009 Application Accepted

  Published as AU-B-2005268844

2 July 2009 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005268845-Condensed pyridines as kinase inhibitors

2005268829-Device for interrupting selectively a rotary translational movement